Vitanova Life Sciences swings to FY26 net loss of USD 37,304; revenue rises 14% to USD 3.03 million
VNOV•FY26 results
Vitanova Life Sciences posted a net loss of USD 37,304 for fiscal 2026, turning from net income of USD 850,746 a year earlier.
Revenue rose 14% to USD 3.03 million, while gross profit fell 42% to USD 910,589.
Cash flow and liquidity
Net cash from operating activities climbed to USD 814,407 from USD 192,774, lifting cash to USD 1.6 million at year-end.
Margin and expense pressure
Gross margin narrowed to 30% from 59%, as the mix shifted toward lower-margin healthy food products priced to build demand.
General and administrative expense more than quadrupled to USD 733,795, driven by higher legal and professional fees and stock compensation.
